A First-in-Class LZK Inhibitor Suppresses Tumor Growth and Potentiates EGFR and PI3K Pathway Blockade in Head and Neck and Esophageal Cancers
Meghri Katerji, Kailey N. Jackett, Maxine R. Rubin, Eric Lindberg, Carolyn C. Woodroofe, Xiaoyi Li, Knickole Bergman, Zoe Weaver Ohler, Stephanie Jorgensen, Xiaohu Zhang, David O. Holland, Mahfuza Sharmin, Amy Funk, Katerine Nyswaner, Noelle Tesi, , John Brognard
This study identifies compound #63 as a potent LZK inhibitor that suppresses tumor growth and enhances EGFR and PI3K pathway blockade in HNSCC and ESCC.
bioRxiv · Oct 20, 2026 · PreprintCancer Biology